Illumina (BSP:I1LM34) DeferredTaxAndRevenue : R$1,235 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Illumina DeferredTaxAndRevenue?

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Illumina's current deferred tax and revenue for the quarter that ended in Dec. 2023 was R$1,235 Mil.

Illumina DeferredTaxAndRevenue Historical Data

The historical data trend for Illumina's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Illumina DeferredTaxAndRevenue Chart

Illumina Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

DeferredTaxAndRevenue

Get a 7-Day Free Trial

685.45

956.91

1,323.25

1,285.12

1,234.75

Illumina Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
DeferredTaxAndRevenue	Get a 7-Day Free Trial															1,285.12	1,343.82	1,213.43	1,195.17	1,234.75

Illumina DeferredTaxAndRevenue Related Terms

Thank you for viewing the detailed overview of Illumina's DeferredTaxAndRevenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Illumina (BSP:I1LM34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Illumina Inc (BSP:I1LM34) » Definitions » DeferredTaxAndRevenue

Comparable Companies

Traded in Other Exchanges

ILMN:USA ILMN:Mexico 1ILMN:Italy ILU:Germany ILU:Germany ILU:Germany ILMN:Austria

Address

5200 Illumina Way, San Diego, CA, USA, 92122

Website

https://www.illumina.com

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates about 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (about 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Illumina (BSP:I1LM34) Headlines

No Headlines